586 related articles for article (PubMed ID: 30016411)
1. Molecular properties underlying regional vulnerability to Alzheimer's disease pathology.
Grothe MJ; Sepulcre J; Gonzalez-Escamilla G; Jelistratova I; Schöll M; Hansson O; Teipel SJ;
Brain; 2018 Sep; 141(9):2755-2771. PubMed ID: 30016411
[TBL] [Abstract][Full Text] [Related]
2. Alzheimer's pathology targets distinct memory networks in the ageing brain.
Maass A; Berron D; Harrison TM; Adams JN; La Joie R; Baker S; Mellinger T; Bell RK; Swinnerton K; Inglis B; Rabinovici GD; Düzel E; Jagust WJ
Brain; 2019 Aug; 142(8):2492-2509. PubMed ID: 31199481
[TBL] [Abstract][Full Text] [Related]
3. Regional distribution of synaptic markers and APP correlate with distinct clinicopathological features in sporadic and familial Alzheimer's disease.
Shinohara M; Fujioka S; Murray ME; Wojtas A; Baker M; Rovelet-Lecrux A; Rademakers R; Das P; Parisi JE; Graff-Radford NR; Petersen RC; Dickson DW; Bu G
Brain; 2014 May; 137(Pt 5):1533-49. PubMed ID: 24625695
[TBL] [Abstract][Full Text] [Related]
4. Combined Connectomics, MAPT Gene Expression, and Amyloid Deposition to Explain Regional Tau Deposition in Alzheimer Disease.
Zheng L; Rubinski A; Denecke J; Luan Y; Smith R; Strandberg O; Stomrud E; Ossenkoppele R; Svaldi DO; Higgins IA; Shcherbinin S; Pontecorvo MJ; Hansson O; Franzmeier N; Ewers M;
Ann Neurol; 2024 Feb; 95(2):274-287. PubMed ID: 37837382
[TBL] [Abstract][Full Text] [Related]
5. Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer's disease.
Rubinski A; Franzmeier N; Dewenter A; Luan Y; Smith R; Strandberg O; Ossenkoppele R; Dichgans M; Hansson O; Ewers M;
Alzheimers Res Ther; 2022 Sep; 14(1):139. PubMed ID: 36153607
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages.
Pascoal TA; Benedet AL; Tudorascu DL; Therriault J; Mathotaarachchi S; Savard M; Lussier FZ; Tissot C; Chamoun M; Kang MS; Stevenson J; Massarweh G; Guiot MC; Soucy JP; Gauthier S; Rosa-Neto P
Brain; 2021 Dec; 144(11):3517-3528. PubMed ID: 34515754
[TBL] [Abstract][Full Text] [Related]
7. Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers.
Gordon BA; Blazey TM; Christensen J; Dincer A; Flores S; Keefe S; Chen C; Su Y; McDade EM; Wang G; Li Y; Hassenstab J; Aschenbrenner A; Hornbeck R; Jack CR; Ances BM; Berman SB; Brosch JR; Galasko D; Gauthier S; Lah JJ; Masellis M; van Dyck CH; Mintun MA; Klein G; Ristic S; Cairns NJ; Marcus DS; Xiong C; Holtzman DM; Raichle ME; Morris JC; Bateman RJ; Benzinger TLS
Brain; 2019 Apr; 142(4):1063-1076. PubMed ID: 30753379
[TBL] [Abstract][Full Text] [Related]
8. Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology.
Perez-Nievas BG; Stein TD; Tai HC; Dols-Icardo O; Scotton TC; Barroeta-Espar I; Fernandez-Carballo L; de Munain EL; Perez J; Marquie M; Serrano-Pozo A; Frosch MP; Lowe V; Parisi JE; Petersen RC; Ikonomovic MD; López OL; Klunk W; Hyman BT; Gómez-Isla T
Brain; 2013 Aug; 136(Pt 8):2510-26. PubMed ID: 23824488
[TBL] [Abstract][Full Text] [Related]
9. Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease.
Dani M; Wood M; Mizoguchi R; Fan Z; Walker Z; Morgan R; Hinz R; Biju M; Kuruvilla T; Brooks DJ; Edison P
Brain; 2018 Sep; 141(9):2740-2754. PubMed ID: 30052812
[TBL] [Abstract][Full Text] [Related]
10. Plasma tau/amyloid-β1-42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer's disease.
Park JC; Han SH; Yi D; Byun MS; Lee JH; Jang S; Ko K; Jeon SY; Lee YS; Kim YK; Lee DY; Mook-Jung I
Brain; 2019 Mar; 142(3):771-786. PubMed ID: 30668647
[TBL] [Abstract][Full Text] [Related]
11. Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia.
Lowe VJ; Wiste HJ; Senjem ML; Weigand SD; Therneau TM; Boeve BF; Josephs KA; Fang P; Pandey MK; Murray ME; Kantarci K; Jones DT; Vemuri P; Graff-Radford J; Schwarz CG; Machulda MM; Mielke MM; Roberts RO; Knopman DS; Petersen RC; Jack CR
Brain; 2018 Jan; 141(1):271-287. PubMed ID: 29228201
[TBL] [Abstract][Full Text] [Related]
12. Dynamic relationships between age, amyloid-β deposition, and glucose metabolism link to the regional vulnerability to Alzheimer's disease.
Oh H; Madison C; Baker S; Rabinovici G; Jagust W
Brain; 2016 Aug; 139(Pt 8):2275-89. PubMed ID: 27190008
[TBL] [Abstract][Full Text] [Related]
13. Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models.
Götz J; Schild A; Hoerndli F; Pennanen L
Int J Dev Neurosci; 2004 Nov; 22(7):453-65. PubMed ID: 15465275
[TBL] [Abstract][Full Text] [Related]
14. Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum.
Jones DT; Graff-Radford J; Lowe VJ; Wiste HJ; Gunter JL; Senjem ML; Botha H; Kantarci K; Boeve BF; Knopman DS; Petersen RC; Jack CR
Cortex; 2017 Dec; 97():143-159. PubMed ID: 29102243
[TBL] [Abstract][Full Text] [Related]
15. Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer's disease.
Strom A; Iaccarino L; Edwards L; Lesman-Segev OH; Soleimani-Meigooni DN; Pham J; Baker SL; Landau SM; Jagust WJ; Miller BL; Rosen HJ; Gorno-Tempini ML; Rabinovici GD; La Joie R;
Brain; 2022 Apr; 145(2):713-728. PubMed ID: 34373896
[TBL] [Abstract][Full Text] [Related]
16. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease.
Kadir A; Marutle A; Gonzalez D; Schöll M; Almkvist O; Mousavi M; Mustafiz T; Darreh-Shori T; Nennesmo I; Nordberg A
Brain; 2011 Jan; 134(Pt 1):301-17. PubMed ID: 21149866
[TBL] [Abstract][Full Text] [Related]
18. Microglial activation and tau burden predict cognitive decline in Alzheimer's disease.
Malpetti M; Kievit RA; Passamonti L; Jones PS; Tsvetanov KA; Rittman T; Mak E; Nicastro N; Bevan-Jones WR; Su L; Hong YT; Fryer TD; Aigbirhio FI; O'Brien JT; Rowe JB
Brain; 2020 May; 143(5):1588-1602. PubMed ID: 32380523
[TBL] [Abstract][Full Text] [Related]
19. Medial Temporal Lobe Networks in Alzheimer's Disease: Structural and Molecular Vulnerabilities.
de Flores R; Das SR; Xie L; Wisse LEM; Lyu X; Shah P; Yushkevich PA; Wolk DA
J Neurosci; 2022 Mar; 42(10):2131-2141. PubMed ID: 35086906
[TBL] [Abstract][Full Text] [Related]
20. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
Bejanin A; Schonhaut DR; La Joie R; Kramer JH; Baker SL; Sosa N; Ayakta N; Cantwell A; Janabi M; Lauriola M; O'Neil JP; Gorno-Tempini ML; Miller ZA; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
Brain; 2017 Dec; 140(12):3286-3300. PubMed ID: 29053874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
